HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shahrokh F Shariat Selected Research

Prostatic Neoplasms (Prostate Cancer)

10/2022Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care.
10/2022Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
10/2022Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients.
9/2022Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy.
6/2022Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery.
6/2022Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile.
5/2022Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
4/2022Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
2/2022MRI as a screening tool for prostate cancer: current evidence and future challenges.
2/2022Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shahrokh F Shariat Research Topics

Disease

409Neoplasms (Cancer)
09/2022 - 02/2002
309Carcinoma (Carcinomatosis)
08/2022 - 12/2002
268Prostatic Neoplasms (Prostate Cancer)
10/2022 - 02/2002
264Urinary Bladder Neoplasms (Bladder Cancer)
11/2022 - 03/2002
93Renal Cell Carcinoma (Grawitz Tumor)
07/2022 - 10/2008
85Neoplasm Metastasis (Metastasis)
06/2022 - 02/2002
56Lymphatic Metastasis
08/2022 - 03/2002
55Non-Muscle Invasive Bladder Neoplasms
08/2022 - 05/2010
37Disease Progression
09/2022 - 02/2002
35Carcinoma in Situ
09/2022 - 03/2003
29Margins of Excision
12/2021 - 03/2004
28Transitional Cell Carcinoma
04/2014 - 03/2002
14Adenocarcinoma
01/2021 - 05/2007
13Kidney Neoplasms (Kidney Cancer)
06/2022 - 09/2012
13Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/2021 - 03/2011
10Inflammation (Inflammations)
06/2022 - 03/2011
9Carcinogenesis
04/2022 - 11/2007
9Necrosis
01/2017 - 04/2010
8Urologic Neoplasms (Urological Cancer)
05/2022 - 06/2013
8Obesity
11/2021 - 08/2007
8Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/2021 - 01/2004
8Intraoperative Complications
01/2018 - 04/2012
7COVID-19
04/2022 - 01/2020
7Extranodal Extension
03/2019 - 06/2004
6Erectile Dysfunction
12/2022 - 09/2008
6Urinary Incontinence
01/2022 - 03/2008
6Anemia
05/2021 - 02/2014
5Lower Urinary Tract Symptoms
12/2022 - 09/2008
5Residual Neoplasm
06/2022 - 08/2009
5Hematuria
02/2016 - 04/2007

Drug/Important Bio-Agent (IBA)

98Biomarkers (Surrogate Marker)IBA
08/2022 - 05/2003
51Prostate-Specific Antigen (Semenogelase)IBA
02/2022 - 10/2002
29Biological ProductsIBA
10/2022 - 10/2003
25AndrogensIBA
05/2022 - 03/2004
20Immune Checkpoint InhibitorsIBA
07/2022 - 01/2018
17Proteins (Proteins, Gene)FDA Link
01/2022 - 05/2007
16Hormones (Hormone)IBA
10/2022 - 10/2002
16nuclear matrix protein 22IBA
11/2014 - 12/2003
15Cisplatin (Platino)FDA LinkGeneric
06/2022 - 06/2008
14Docetaxel (Taxotere)FDA Link
10/2022 - 01/2018
13AntigensIBA
06/2022 - 03/2008
13Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
11/2021 - 12/2002
11Interleukin-6 (Interleukin 6)IBA
01/2022 - 03/2002
11SurvivinIBA
11/2015 - 02/2004
10AlbuminsIBA
03/2022 - 06/2014
10GlobulinsIBA
03/2022 - 01/2020
10Indicators and Reagents (Reagents)IBA
09/2021 - 04/2010
9Androgen Receptors (Androgen Receptor)IBA
06/2022 - 01/2008
9pembrolizumabIBA
01/2022 - 01/2019
9Tyrosine Kinase InhibitorsIBA
01/2022 - 09/2014
9Cadherins (E-Cadherin)IBA
08/2017 - 12/2003
8Messenger RNA (mRNA)IBA
01/2022 - 04/2003
8Dihydrotachysterol (AT 10)IBA
01/2021 - 12/2009
8Urokinase Plasminogen Activator ReceptorsIBA
10/2020 - 12/2002
7EnzymesIBA
04/2022 - 12/2002
7PlatinumIBA
03/2022 - 10/2011
7enzalutamideIBA
01/2022 - 01/2020
7Hemoglobins (Hemoglobin)IBA
05/2021 - 02/2014
7Plasminogen Activators (Plasminogen Activator)IBA
01/2021 - 03/2008
6Testosterone (Sustanon)FDA Link
12/2022 - 01/2008
6DNA (Deoxyribonucleic Acid)IBA
05/2022 - 12/2011
6EndoglinIBA
01/2022 - 03/2008
6Pharmaceutical PreparationsIBA
01/2022 - 12/2007
6CyclinsIBA
11/2016 - 12/2006
5Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
08/2022 - 05/2004
5LigandsIBA
06/2022 - 12/2018
5GemcitabineFDA Link
01/2022 - 06/2008
5C-Reactive ProteinIBA
01/2022 - 11/2016
5Serum AlbuminIBA
10/2021 - 01/2021
5mesoglycanIBA
05/2021 - 07/2015
5PlasminogenIBA
01/2021 - 05/2003
5ParaffinIBA
12/2015 - 03/2003
5Transforming Growth Factor beta1 (TGF beta 1)IBA
06/2009 - 10/2003
4Caveolin 1IBA
08/2022 - 05/2007
4Androgen Antagonists (Antiandrogens)IBA
05/2022 - 01/2008
4abirateroneIBA
01/2022 - 01/2020
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 05/2004
4Carrier Proteins (Binding Protein)IBA
01/2022 - 07/2012

Therapy/Procedure

253Cystectomy
09/2022 - 03/2002
191Therapeutics
09/2022 - 10/2002
170Prostatectomy (Retropubic Prostatectomy)
10/2022 - 02/2002
141Nephroureterectomy
03/2022 - 10/2008
102Lymph Node Excision (Lymph Node Dissection)
06/2022 - 03/2004
96Drug Therapy (Chemotherapy)
07/2022 - 12/2006
85Nephrectomy
07/2022 - 04/2007
75Radiotherapy
02/2022 - 04/2003
53Adjuvant Chemotherapy
06/2022 - 10/2006
38Neoadjuvant Therapy
07/2022 - 10/2006
32Castration
10/2022 - 04/2012
24Immunotherapy
05/2022 - 12/2012
18Transurethral Resection of Bladder
04/2022 - 03/2013
16Length of Stay
02/2022 - 08/2011
14Blood Transfusion (Blood Transfusions)
01/2019 - 04/2007
7Thrombectomy
06/2022 - 09/2014
7Aftercare (After-Treatment)
01/2022 - 03/2004
6Brachytherapy
01/2022 - 05/2017
5Conservative Treatment
09/2022 - 09/2008
5Urinary Diversion (Ileal Conduit)
07/2022 - 12/2013
5Precision Medicine
05/2021 - 01/2018
5Intravesical Administration
01/2018 - 10/2013